ESG in pharma: has the ‘S’ reached a turning point? – Barings

Only members with restricted access (ie. academics, asset owners, government and regulatory, independent advisers/trustees and sponsoring employers) can view this article. Please login or join to view.

Barings’ Head of Global Health Care Research—Equities, Alexandra Hillier, discusses how increased regulation and heightened competition are transforming the pharma industry’s behaviour when it comes to the pricing and availability of medicine.

Learn more here

Phone:
01234 388845

Email:
Event enquiries
Finance enquiries
General enquiries
Membership enquiries
Press enquiries
Training enquiries

Address:
226B Oving Road
Chichester
West Sussex
PO19 7EJ

Pensions for Purpose acts as an information centre only. We do not endorse any content published on this website that originated from one of our members. For more information, please see the website terms of use

Tweets by Pensions for Purpose

Keep updated:

ESG in pharma: has the ‘S’ reached a turning point? – Barings

Social may be an area where pharma companies have the greatest potential for progress.

Only members with restricted access (ie. academics, asset owners, government and regulatory, independent advisers/trustees and sponsoring employers) can view this article. Please login or join to view.

Sign up to our newsletter